KR940005558A - 옥심 유도체 - Google Patents
옥심 유도체 Download PDFInfo
- Publication number
- KR940005558A KR940005558A KR1019930013623A KR930013623A KR940005558A KR 940005558 A KR940005558 A KR 940005558A KR 1019930013623 A KR1019930013623 A KR 1019930013623A KR 930013623 A KR930013623 A KR 930013623A KR 940005558 A KR940005558 A KR 940005558A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- alkyl
- phenyl
- yloxy
- acetic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/20—Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
- C07C251/54—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
본 발명은 하기 일반식(I)의 옥심 유도체 및 이의 염에 관한 것이며, 이들은 PGl2수용체에서 작용 작용을 지녀서 혈전증, 동맥경화증, 허혈성 심장발작, 위궤양 및 고혈압의 예방 및/또는 치료에 유용한 것으로 기대된다:
상기식에서, D고리 및 D고리에서의 B 결합은 (i)-(iv)이며, 이때, R1은 수소, 저급 알킬이고, R2는 수소, 알킬, 페닐, 시클로알킬, 질소를 함유한 모노시클릭 고리, 벤젠 고리 또는 시클로알킬로 치환된 저급 알킬, 질소를 함유한 모노시클릭 고리로 치환된 저급 알킬이고, R3는 알킬, 페닐, 시클로알킬, 질소를 함유한 모노시클릭 고리, 벤젠 고리 또는 시클로알킬로 치환된 저급 알킬, 질소를 함유한 모노시클릭 고리로 치환된 저급 알킬이고, e는 3-5이고, f는 1-3이고, p는 1-4이고, q는 1-2이고, r은 1-3이고, (ⅲ)- (ⅳ)의 D고리로의 결합 위치는 a 또는 b이고, R2및 R3의 고리는 저급 알킬, 알콕시, 할로겐, 니트로, 트리할로메틸로 치환될 수 있다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (15)
- 하기 일반식(Ⅰ)의 옥심 유도체 및 이의 비독성염:(Ⅰ)상기 식에서,은(ⅰ)(ⅱ)(ⅲ)또는(ⅳ)이고;R1은 수소 또는 C1-4알킬이고, R2는 (i)수소, (ⅱ)C1-8알킬, (ⅲ)페닐 또는 C4-7시클로알킬, (iv)1개의 질소를 함유한 4-7원 모노시클릭 고리, (v)벤젠 고리 또는 C4-7시클로알킬로 치환된 C1-4알킬 또는 (vi)1개의 질소를 함유한 4-7원 모노시 클릭 고리로 치환된 C1-4알킬이며, R3는 (i)C1-8알킬, (ⅱ)페닐 또는 C4-7시클로알킬, (Ⅲ)1개의 질소를 함유한 4-7원 모노시클릭 고리, (iv)벤질 고리 또는 C4-7시클로알킬로 치환된 C1-4알킬 또는 (ⅴ)1개의 질소를 함유한 4-7원 모노시클릭 고리로 치환된 C1-4알킬이며, e는 3-5이고; f는 1-3이고, p는 1-4이고, q는 1-2이고, r은 1-3이고,가 일반식 (ⅲ) 또는 (ⅳ)일 때, -(CH2)P- 및 = CH-(CH2)S-는 고리의 a 또는 b의 위치에서 결합되며, R2및 R3내의 고리는 하나 내지 세개의 C1-4알킬, C1-4알콕시, 할로겐, 니트로 또는 트리할로메틸로 치환될 수 있다.
- 제1항에 있어서,가 (ⅰ)인 화합물.
- 제1항에 있어서,가 (ⅱ)인 화합물.
- 제1항에 있어서,가 (ⅲ)인 화합물.
- 제1항에 있어서,가 (ⅳ)인 화합물.
- 제1항에 있어서, R2가 C1-8알킬인 화합물.
- 제1항에 있어서, R2가 페닐 또는 C4-7시클로알킬인 화합물.
- 제1항에 있어서, R2가 1개의 질소를 함유한 4-7원 헤테로시클릭 단일 고리인 화합물.
- 제1항에 있어서, R2가 피리딘 고리인 화합물.
- 제1항에 있어서, R2가 페닐 또는 C4-7시클로알킬로 치환된 C1-4알킬인 화합물.
- 제1항에 있어서, R2가 1개의 질소를 함유한 4-7원 헤테로시클릭 단일 고리로 치환된 C1-4알킬인 화합물.
- 제1항에 있어서, 하기와 같은 화합물 : [5-[2-[1-페닐-1-(3-피디딜)메틸리덴아미노옥시]에틸]-5,6,7,8-테트라히드로나프탈렌-1-일옥시]아세트산, [5-[2-(디페닐메틸리덴아미노옥시]에틸]-5,6,7,8-테트라히드로나프탈렌-1-일옥시]아세트산, [1-[2-(1-페닐-1-(3-피디딜)메틸리덴아미노옥시]에틸]-2,3-디히드로인덴-4-일옥시]아세트산, [6-[1-(1-페닐-1-(3-피디딜)메틸리덴아미노옥시]메틸]-5,6,7,8-테트라히드로나프탈렌-1-일옥시]아세트산, [6-[1-[1-페닐-1-(3-피디딜)메틸리덴아미노옥시]에틸]-7,8-디히드로나프탈렌-1-일옥시]아세트산, [5-[2-[1,1-(3-디피디딜)메틸리덴아미노옥시]에틸]-5,6,7,8-테트라히드로나프탈렌-1-일옥시]아세트산, [5-[2-[1-페닐-1-(3-피디딜)메틸리덴아미노옥시]에틸]-7,8-디히드로나프탈렌-1-일옥시]아세트산, [5-[2-[l-페닐-(3-피디딜)메틸리덴아미노옥시]에틸리덴]-5,6,7,8-테트라히드로나프탈렌-1-일옥시]아세트산 또는 [5-[3-(디페닐메틸리덴아미노옥시)-1-프로페닐]-5,6,7,8-테트라히드로나프탈렌-1-일옥시]아세트산.
- 하기 일반식(Ⅱ)의 화합물 및 하기 일반식(Ⅲ)의 화합물을 반응시키고, 필요할 경우, 알카리 조건하에서 가수분해시키고 및/또는 환훤시키는것을 특징으로 하는 하기 일반식(I)의 화합물을 제조하는 방법.(Ⅰ)(Ⅱ)(Ⅲ)상기식에서, R1a는 C1-4알킬이고, X는 할로겐 또는 메실옥시이고, 다른 기호들은 제1항에서 정의된 것과 동일한 의미를 갖는다.
- 활성성분으로서, 유효량의 제1항에서 도시된 일반식(I)의 화합물 또는 이의 약학적으로 허용가능한 염, 약학적 담체 또는 코팅물을 포함하는 약학적 조성물.
- 유효량의 제1항에서 도시된 일반식(I)의 화합물 또는 이의 약학적으로 허용가능한 염을 투여하는 것을 포함하는, 혈전증, 동맥경화증, 허혈증 심장발작, 위궤양 또는 고혈압의 예방 및/또는 치료에서 사용하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP92-215457 | 1992-07-21 | ||
JP21545792 | 1992-07-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR940005558A true KR940005558A (ko) | 1994-03-21 |
KR100191137B1 KR100191137B1 (ko) | 1999-06-15 |
Family
ID=16672692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019930013623A KR100191137B1 (ko) | 1992-07-21 | 1993-07-20 | 옥심 유도체 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5480998A (ko) |
EP (1) | EP0581187B1 (ko) |
JP (2) | JP2691679B2 (ko) |
KR (1) | KR100191137B1 (ko) |
AT (1) | ATE145892T1 (ko) |
CA (1) | CA2100918C (ko) |
DE (1) | DE69306324T2 (ko) |
DK (1) | DK0581187T3 (ko) |
ES (1) | ES2097402T3 (ko) |
GR (1) | GR3022576T3 (ko) |
TW (1) | TW281668B (ko) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6043264A (en) * | 1995-01-06 | 2000-03-28 | Toray Industries, Inc. | Benzene-condensed heterocyclic derivatives and their uses |
US5723666A (en) * | 1996-06-21 | 1998-03-03 | Allergan | Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
DE19722848A1 (de) * | 1997-05-23 | 1998-11-26 | Schering Ag | Leukotrien-B¶4¶-Derivate, insbesondere Oximo-LTB¶4¶-Antagonisten |
EP1065233A1 (en) * | 1998-02-27 | 2001-01-03 | Ono Pharmaceutical Co., Ltd. | Carrier polymers migrating into target organs and drug-containing polymers |
AR029876A1 (es) | 1998-05-11 | 2003-07-23 | Takeda Pharmaceutical | Compuesto de acido oxiiminoalcanoilo, composicion farmaceutica y agente para controlar receptores relacionados con retinoide que lo comprenden y su uso |
AU5249200A (en) * | 1999-06-21 | 2001-01-09 | Fujisawa Pharmaceutical Co., Ltd. | Remedies for skin ulcer |
WO2004032965A1 (ja) | 2002-10-10 | 2004-04-22 | Ono Pharmaceutical Co., Ltd. | 内因性修復因子産生促進剤 |
EP1627638B1 (en) | 2003-05-09 | 2017-07-12 | Toray Industries, Inc. | Beraprost and a renin-angiotensin system inhibitor for use in the treatment of renal diseases |
PL2087890T3 (pl) * | 2006-10-19 | 2014-08-29 | Ono Pharmaceutical Co | Preparat o przedłużonym uwalnianiu do terapii regeneracyjnej tkanki |
WO2014046065A1 (ja) | 2012-09-21 | 2014-03-27 | 国立大学法人大阪大学 | 心筋・血管再生デバイスとしての重症心不全治療材 |
JP6400479B2 (ja) | 2012-10-29 | 2018-10-03 | 株式会社カルディオ | 肺疾患特異的治療剤 |
US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
US20190343841A1 (en) | 2016-12-27 | 2019-11-14 | Osaka University | Medicinal Composition for Treating Intractable Heart Disease |
WO2019102606A1 (ja) | 2017-11-27 | 2019-05-31 | 国立大学法人大阪大学 | 疾患部位特異的リポソーム製剤 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0004329A1 (de) * | 1978-03-17 | 1979-10-03 | Hagus C. Luchtenberg GmbH & Co. KG | Zusatzrückspiegel für Kraftfahrzeuge |
US4352804A (en) * | 1978-07-25 | 1982-10-05 | Acf Chemiefarma Nv | Oxime ethers, their preparation and pharmaceutical compositions containing them |
JPH025739B2 (ko) * | 1979-01-05 | 1990-02-05 | Nat Res Dev | |
ZA829068B (en) * | 1980-07-01 | 1983-02-23 | Nat Res Dev | Prostaglandins |
DE3504677A1 (de) * | 1985-02-12 | 1986-08-14 | A. Nattermann & Cie GmbH, 5000 Köln | Neue imidazol-2-yloxyalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
FI92189C (fi) * | 1986-03-17 | 1994-10-10 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisen difenyylimetaanijohdannaisen valmistamiseksi |
JP2765876B2 (ja) * | 1988-10-24 | 1998-06-18 | 科研製薬株式会社 | ピリジルケトオキシムエーテル誘導体 |
US5344836A (en) * | 1991-11-11 | 1994-09-06 | Ono Pharmaceutical Co., Ltd. | Fused benzeneoxyacetic acid derivatives |
-
1993
- 1993-07-20 KR KR1019930013623A patent/KR100191137B1/ko not_active IP Right Cessation
- 1993-07-20 JP JP5200345A patent/JP2691679B2/ja not_active Expired - Lifetime
- 1993-07-20 CA CA002100918A patent/CA2100918C/en not_active Expired - Fee Related
- 1993-07-21 DE DE69306324T patent/DE69306324T2/de not_active Expired - Fee Related
- 1993-07-21 ES ES93111689T patent/ES2097402T3/es not_active Expired - Lifetime
- 1993-07-21 AT AT93111689T patent/ATE145892T1/de not_active IP Right Cessation
- 1993-07-21 EP EP93111689A patent/EP0581187B1/en not_active Expired - Lifetime
- 1993-07-21 DK DK93111689.1T patent/DK0581187T3/da active
- 1993-07-23 TW TW082105895A patent/TW281668B/zh active
-
1994
- 1994-03-17 US US08/215,019 patent/US5480998A/en not_active Expired - Fee Related
-
1995
- 1995-09-20 JP JP7264666A patent/JP2649507B2/ja not_active Expired - Fee Related
-
1997
- 1997-02-19 GR GR960403290T patent/GR3022576T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0581187A1 (en) | 1994-02-02 |
JP2649507B2 (ja) | 1997-09-03 |
ES2097402T3 (es) | 1997-04-01 |
GR3022576T3 (en) | 1997-05-31 |
KR100191137B1 (ko) | 1999-06-15 |
JP2691679B2 (ja) | 1997-12-17 |
TW281668B (ko) | 1996-07-21 |
DE69306324D1 (de) | 1997-01-16 |
CA2100918C (en) | 1997-01-21 |
DE69306324T2 (de) | 1997-05-22 |
ATE145892T1 (de) | 1996-12-15 |
JPH08109162A (ja) | 1996-04-30 |
DK0581187T3 (da) | 1996-12-23 |
US5480998A (en) | 1996-01-02 |
EP0581187B1 (en) | 1996-12-04 |
CA2100918A1 (en) | 1994-01-22 |
JPH0687811A (ja) | 1994-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR940005558A (ko) | 옥심 유도체 | |
KR880003935A (ko) | (1h-이미다졸-1-일메틸)치환된 벤즈이미다졸 유도체 | |
NO904134D0 (no) | Fremgangsmaate for fremstilling av pyrazolderivater. | |
ATE193828T1 (de) | Hypoglykämische dihydrochalconderivate | |
KR960031462A (ko) | 복소환식 화합물 | |
IE860618L (en) | Indole derivatives | |
KR920021514A (ko) | 피리딘 유도체, 이의 제법 및 용도 | |
KR950000659A (ko) | 항-고콜레스테롤혈증 활성을 갖는 아미드 및 우레아 유도체, 그의 제조방법 및 그의 치료학적 용도 | |
KR930701415A (ko) | 약학적으로 활성인 벤조퀴나졸린 화합물 | |
KR940014384A (ko) | 항바이러스제로서의 페녹시- 및 페녹시알킬-피페리딘 | |
ATE177096T1 (de) | 4-substituierte 1,2,4-triazolderivate | |
KR970061873A (ko) | 피리다지논 유도체 및 이것의 제조 방법 | |
IL144813A0 (en) | Heterocyclic compounds, intermediates thereof and elastase inhibitors | |
KR920019779A (ko) | 치환된 인돌의 n-이미다졸릴 유도체 | |
ATE402151T1 (de) | 2-(arylphenyl)amino-imidazolin-derivate | |
KR920002541A (ko) | 아릴 아미노 카르보닐 화합물 | |
KR870007153A (ko) | 티아나프텐 유도체 및 이의 제조 방법 | |
KR960022438A (ko) | 나프틸옥시아세트산 유도체 | |
FR2612925B1 (fr) | Derives triaziniques de 2,2,6,6-tetramethylpiperidines, compositions de matieres organiques contenant ces derives et leur emploi pour proteger des matieres organiques contre les degradations provoquees par la chaleur, la lumiere ou l'oxydation | |
HU9602534D0 (en) | Use of biphenyl methyl imidazole derivatives for producing pharmaceutical compositions having ocular tension derpessant activity | |
KR940002214A (ko) | 융합 벤젠옥시아세트산 유도체 | |
KR970001357A (ko) | 접합고리 피리딘을 함유한 벤즈이미다졸 유도체 | |
ATE257382T1 (de) | 3-carboalkoxy-2,3-dihydro-1h-phenothiazin-4(10h - one derivate | |
KR870700636A (ko) | 고혈압 치료제 이를 함유하는 약제학적 조성물 및 고혈압 치료제 및 조성물을 제조하는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20070110 Year of fee payment: 9 |
|
LAPS | Lapse due to unpaid annual fee |